GLP-1 (glucagon-like peptide-1) therapies can be powerful tools in managing obesity, with patients taking these medications seeing weight reductions of 5%–18% in clinical trials, along with increased metabolism and benefits to their overall heart health. However, GLP-1s can come with challenges, including gastrointestinal side effects, risk of micronutrient deficiencies, muscle and bone loss, poor long-term follow-through with weight regain if stopped, and high costs.
This article was originally published on MedicalXpress.com
